{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "firstTradeDateMilliseconds": 1423209600000, "priceHint": 4, "epsTrailingTwelveMonths": -1.01, "epsForward": -1.2, "sharesOutstanding": 31883600, "bookValue": -0.124, "fiftyDayAverage": 0.70332, "fiftyDayAverageChange": -0.08832002, "fiftyDayAverageChangePercent": -0.12557586, "twoHundredDayAverage": 1.27398, "twoHundredDayAverageChange": -0.65898, "twoHundredDayAverageChangePercent": -0.51726085, "marketCap": 19608414, "forwardPE": -0.5125, "priceToBook": -4.9596777, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChangePercent": -5.3846107, "regularMarketPrice": 0.615, "marketState": "POSTPOST", "exchange": "PAR", "shortName": "POXEL", "longName": "Poxel S.A.", "messageBoardId": "finmb_109129442", "exchangeTimezoneName": "Europe/Paris", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "fr_market", "esgPopulated": false, "regularMarketChange": -0.034999967, "regularMarketTime": 1683905879, "regularMarketDayHigh": 0.654, "regularMarketDayRange": "0.621 - 0.654", "regularMarketDayLow": 0.621, "regularMarketVolume": 201268, "regularMarketPreviousClose": 0.65, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Paris", "financialCurrency": "EUR", "regularMarketOpen": 0.639, "averageDailyVolume3Month": 116319, "averageDailyVolume10Day": 90738, "fiftyTwoWeekLowChange": 0.022000015, "fiftyTwoWeekLowChangePercent": 0.037099518, "fiftyTwoWeekRange": "0.593 - 2.815", "fiftyTwoWeekHighChange": -2.2, "fiftyTwoWeekHighChangePercent": -0.7815275, "fiftyTwoWeekLow": 0.593, "fiftyTwoWeekHigh": 2.815, "earningsTimestamp": 1684321140, "earningsTimestampStart": 1684321140, "earningsTimestampEnd": 1684321140, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "POXEL.PA"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Immeuble Le Sunway", "address2": "259-261 Avenue Jean JaurEs", "city": "Lyon", "zip": "69007", "country": "France", "phone": "33 4 37 37 20 10", "fax": "33 4 37 70 88 15", "website": "https://www.poxelpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). Poxel S.A. has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. The company was incorporated in 2009 and is headquartered in Lyon, France.", "fullTimeEmployees": 55, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Kuhn M.B.A., Pharm.D., Pharm D MBA", "title": "Co-Founder, CEO & Director", "fiscalYear": 2020, "totalPay": {"raw": 398542, "fmt": "398.54k", "longFmt": "398,542"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. S\u00e9bastien  Bolze Ph.D., Pharm.D., Pharm D Ph.D.", "title": "Co-Founder, COO & Exec. VP", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Pascale  Fouqueray-Grellier M.D., Ph.D.", "title": "Co-Founder and Exec. VP of Clinical Devel. & Regulatory Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Sophie  Hallakou-Bozec Ph.D.", "title": "Co-Founder and Sr. VP of R&D Pharmacology & Scientific Communication", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David E. Moller M.D.", "title": "Exec. VP & Chief Scientific Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Elizabeth  Woo M.B.A.", "title": "Sr. VP of Investor Relations, Corp. Communications & PR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Quentin  Durand", "title": "Exec. VP, Chief Legal Officer & Head of CSR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Sylvie  Bertrand", "title": "VP of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Noah D. Beerman MBA", "age": 60, "title": "Exec. VP of Bus. Devel. & Pres of US Operations", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 4, "overallRisk": 9, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1609372800, "maxAge": 86400}}], "error": null}}